Drug Profile
Research programme: HIV integrase inhibitors - Pharmacor
Alternative Names: HIV integrase inhibitors research programme - PharmacorLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Pharmacor
- Class
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 22 Mar 2006 Discontinued - Preclinical for HIV infections treatment in Canada (unspecified route)
- 07 May 2003 Pharmacor has been acquired by Procyon Biopharma
- 23 Dec 2002 This programme is still in active development